Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
AliveCor · NCT06271577
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 1000
- US sites recruiting
- 2
- Study start
- March 12, 2024
- Record last updated
- April 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).
Recently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.
Being studied: AliveCor 12-lead ECG
Conditions: Myocardial Infarction; Ischemia; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Heart Attack; Heart Failure
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male or female > 18 years of age.
- Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
- Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.
Exclusion Criteria
- Inability or refusal of the patient and/or the patient's legally acceptable representative to provide written informed consent for any reason.
- Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.
Recruiting US locations
Mayo Clinic
Rochester, MN 55905
Site contact: Julianne Rumer · 507-255-1034 · Rumer.Julianne@mayo.edu
Intermountain Health
Murray, UT 84107
Site contact: Heather Maestas · 801-680-1931 · Heather.Maestas@imail.org
Study contacts (from the official record)
- Kimberly Roohi, MS · 855-338-8800 · kroohi730@alivecor.com
Similar studies in Minnesota
All heart & blood pressure studies in Minnesota →- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Rochester, MN + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
BoxX-NoAF Clinical Trial
AtriCure, Inc.
- Location
- Rochester, MN + 30 other US sites
- Eligibility basics
- Ages 65+
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Minneapolis, MN + 64 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Merck Sharp & Dohme LLC
- Location
- Minneapolis, MN + 23 other US sites
- Eligibility basics
- Ages 18+